Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) jumped 4% no news. The company offered its corporate updates and financial results for Q2 2021. At the end of the quarter, the company had cash and equivalents of $33.1 million, which is adequate to support completing its clinical studies for its flagship treatment candidate Seclidemstat. CEO David Arthur said that the second quarter was a considerable development period for the company, shown by the significant progress made in various clinical programs resulting in several data readouts in 20201 and 2021.
Arthur said that the company added Fox Chase Cancer Center as its ninth sarcoma clinical study site with ongoing recruitment and treatment of patients with seclidemstat across five patient groups. The groups include two in high unmet hematologic cancer and the other three in sarcomas. In addition, during ASCO 2021, the company released encouraging data.
Its Ewing sarcoma program now offers a chance to study seclidemstat treatment combined with chemo agents where there has been synergistic drug activity. With these clinical developments, SLRX is worth watching.